Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Also Known As:

Antiresorptive Agents; Antiresorptive Drugs; Bone Resorption Inhibitors; Bone Resorption Inhibitory Agents; Agent, Antiresorptive; Inhibitors, Bone Resorption; Resorption Inhibitors, Bone; Antiresorptive Agent

Networked: 703 relevant articles (38 outcomes, 63 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Physiological Effects of Drugs: 1
    - Bone Density Conservation Agents: 703

Experts

1.	Bilezikian, John P: 9 articles (09/2011 - 03/2002)
2.	Cosman, Felicia: 8 articles (01/2021 - 12/2005)
3.	Ohta, Hiroaki: 7 articles (01/2017 - 04/2005)
4.	Taguchi, Akira: 6 articles (01/2022 - 12/2015)
5.	Hayashida, Saki: 5 articles (12/2022 - 01/2020)
6.	Umeda, Masahiro: 5 articles (12/2022 - 01/2020)
7.	Fusco, Vittorio: 5 articles (09/2022 - 02/2014)
8.	Body, Jean-Jacques: 5 articles (01/2022 - 04/2003)
9.	Lane, Joseph M: 5 articles (01/2021 - 05/2003)
10.	Hofbauer, Lorenz C: 5 articles (11/2017 - 03/2002)

Related Diseases

1.	Osteoporosis 01/01/2021 - "Antiresorptive agents are generally recommended as first-line treatment for osteoporosis in postmenopausal women. " 12/01/2023 - "The limited options of anabolic drugs restrict their application potential in osteoporosis treatment, despite their theoretical superiority in therapeutic efficacy over antiresorptive drugs. " 01/01/2001 - "Because of its bone anabolic action, PTH is expected to be effective for osteoporosis in those of advanced age with suppressed bone remodelling, which might not respond favourably to antiresorptive agents." 06/01/1998 - "Several studies indicate that screening for these bone markers may be useful for improving the prognostic assessment of postmenopausal women in combination with bone mass measurement, that is, their risk for osteoporosis and, ultimately, for fractures and to monitor rapidly the efficacy of antiresorptive drugs." 10/01/2018 - "However, the efficacy of antiresorptive drugs against this form of osteoporosis has not been extensively evaluated. "
2.	Postmenopausal Osteoporosis 01/01/2005 - "Antiresorptive agents are effective in preventing and treating postmenopausal osteoporosis, provided they are taken as directed. " 08/01/2008 - "The incidence of ICR during treatment with antiresorptive agents among patients with severe postmenopausal osteoporosis in a routine setting is considerably higher than that observed in randomized clinical trials." 09/01/2022 - "Patients included were affected by postmenopausal osteoporosis and were administered with different antiresorptive drugs. " 01/01/2021 - "Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: A model-based meta-analysis." 01/01/2017 - "In clinical practice, patients with postmenopausal osteoporosis have often shown a poor response to treatment with an antiresorptive agent for several years. "
3.	Neoplasms (Cancer) 01/01/2015 - "In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown to improve bone mineral density (BMD) and to reduce the risk of fractures. " 12/01/2016 - "Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. " 01/01/2014 - "Our recent observations indicated that a decline in the ability of the immune cells to recognize and kill the tumor drives tumor dissemination to bone even when osteoclasts are inhibited by potent antiresorptive agents. " 07/01/2012 - "An appreciation for the high incidence of SRE in other advanced cancers involving the bone has led to the approval of potent antiresorptive agents because they delay the time to the first SRE and decrease the incidence of SRE. " 10/01/2012 - "This review summarises the current data on the course of cancer in clinical trials of the antiresorptive agents and provides important insight into the relative anticancer potential of the various therapies."
4.	Bone Resorption 12/01/1999 - "The antiresorptive agent employed in this study effectively reduced turnover of subchondral bone in the OA joint, consistent with the coupling of bone formation to bone resorption at that site. " 12/27/2020 - "ARONJ is a major concern in patients administered antiresorptive agents for conditions associated with pathologically increased bone resorption. " 10/01/2018 - "Diseases with increased bone resorption are widely treated with antiresorptive drugs. " 01/01/2018 - "On the other hand, bone resorption markers respond to bone resorption inhibitors within a few weeks. " 03/01/2015 - "Importantly, to date, the available antiresorptive drugs have also an inhibiting, though to a lesser extent, effect on bone apposition and, similarly, the anabolic drugs lead to an increase also of bone resorption. "
5.	Back Pain (Backache) 01/01/2006 - "Teriparatide [rhPTH (1-34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated patients had reduced incidence of back pain relative to placebo or to antiresorptive drugs. " 05/01/2023 - "She went on to be treated with an alternative antiresorptive agent, risedronate, and had substantial declines in her bone turnover markers, along with clinical improvement in her back pain. "

Related Drugs and Biologics

1.	Diphosphonates (Bisphosphonates)
2.	Denosumab
3.	Teriparatide (Parathar)
4.	Alendronate (Alendronate Sodium)
5.	Risedronic Acid (Actonel)
6.	Anabolic Agents
7.	Glucocorticoids
8.	Hormones (Hormone)
9.	Etidronic Acid (HEDP)
10.	Aromatase Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Tooth Extraction (Tooth Extractions)
4.	Operative Surgical Procedures
5.	Kidney Transplantation